シンポジウム1「認知症創薬企業セッション　Industry session for drug development」

[SY1-4] Latest results and next development steps for trontinemab in Alzheimer’s disease

^○Janice Smith¹, Luka Kulic², Gregory Klein², Christopher Lane¹, Angeliki Thanasopolou², Jakub Wojtowicz², Carsten Hofmann², Silke Ahlers³, Steven Salloway⁴, Gil Rabinovici⁵, Catherine Mummery⁶, Hanno Svoboda² (1.Roche Products Ltd., Hexagon Place, Shire Park, Welwyn Garden City, 2.F. Hoffmann-La Roche Ltd, Basel, Switzerland, 3.Excelya Germany GmbH, Mannheim, Germany, 4.Butler Hospital and Warren Alpert Medical School, Brown University, Providence, RI, USA, 5.Weill Institute for Neurosciences, and Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA, 6.Queen Square Institute of Neurology, University College London, London, UK)

閲覧にはパスワードが必要です

抄録の閲覧には、パスワードが必要です。
※パスワード：抄録集のP.9、参加登録（決済完了後）のページにてご確認ください。